The Society of Nuclear Medicine and Molecular Imaging (SNMMI) highlighted results of a study in which three patients with solitary fibrous tumors achieved a near-complete response after treatment with yttrium-90 (Y-90) fibroblast activation protein inhibitor (FAPI)-46.
Solitary fibrous tumors (SFTs) are a rare type of soft tissue tumor with few treatment options. Although most SFTs are classified as benign with minimal risk of recurrence, about 15% to 20% are malignant, with poor outcomes for patients.
“This is the first time we have seen such strong and deep responses in advanced SFT using this precision radiation approach,” noted Rainer Hamacher, MD, of the West German Cancer Center at University Hospital Essen, in a news release.
The study included three patients who had already tried multiple standard therapies without success. Molecular analysis of their tumor tissues revealed remarkably high levels of the FAP protein. Patients received four cycles of Y-90 FAPI-46, and their treatment response was evaluated with F-18 FDG and gallium-68 FAPI-46 PET/CT.
The full news release and a link to the article are available here.